Literature DB >> 22890124

Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.

Tony Sheldon.   

Abstract

Mesh：

Year:  2012        PMID： 22890124     DOI： 10.1136/bmj.e5461

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

2.  The legal imperative for treating rare disorders.

Authors:  Hanna I Hyry; Jonathan C P Roos; Jeremy Manuel; Timothy M Cox
Journal:  Orphanet J Rare Dis       Date:  2013-09-06       Impact factor: 4.123

3.  Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.

Authors:  Tim A Kanters; Ans T van der Ploeg; Michelle E Kruijshaar; Dimitris Rizopoulos; W Ken Redekop; Maureen P M H Rutten-van Mӧlken; Leona Hakkaart-van Roijen
Journal:  Orphanet J Rare Dis       Date:  2017-12-13       Impact factor: 4.123

4.  Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.

Authors:  Adam Hutchings; Carina Schey; Richard Dutton; Felix Achana; Karolina Antonov
Journal:  Orphanet J Rare Dis       Date:  2014-02-13       Impact factor: 4.123

5.  Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.

Authors:  Thomas Morel; Francis Arickx; Gustaf Befrits; Paolo Siviero; Caroline van der Meijden; Entela Xoxi; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-12-24       Impact factor: 4.123

6.  Orphan drugs expenditure in the Netherlands in the period 2006-2012.

Authors:  Tim A Kanters; Adri Steenhoek; Leona Hakkaart
Journal:  Orphanet J Rare Dis       Date:  2014-10-11       Impact factor: 4.123

Review 7.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.